Chardan Capital Markets initiates Opus Genetics stock with Buy rating
PositiveFinancial Markets

Chardan Capital Markets has initiated coverage of Opus Genetics with a 'Buy' rating, signaling strong confidence in the company's potential for growth. This endorsement is significant as it may attract more investors and boost the stock's performance, highlighting Opus Genetics' promising developments in the biotech sector.
— Curated by the World Pulse Now AI Editorial System